CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TIMM50 (ImmuneEditome ID:92609)

1. Gene summary of enriched editing regions for TIMM50

check button Gene summary
Gene informationGene symbol

TIMM50

Gene ID

92609

GeneSynonymsMGCA9|TIM50|TIM50L
GeneCytomap

19q13.2

GeneTypeprotein-coding
GeneDescriptionmitochondrial import inner membrane translocase subunit TIM50|Tim50-like protein|homolog of yeast Tim50
GeneModificationdate20230329
UniprotIDQ3ZCQ8;A0A024R0M6;M0R2F8;M0R2Q2;M0R1Y4;M0R2D2
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:39483922-39485272:+ENST00000597782.4ENSG00000105197.9TIMM50exonicAluSc,AluJr,FLAM_C,AluSx,MER20chr19:39483922-39485272:+.alignment
chr19:39490389-39493428:+ENST00000595527.2ENSG00000105197.9TIMM50ncRNA_exonicAluJr,AluJb,AluJo,AluSx,MER102b,MIR,MIRb,AluSx1,AluSp,MER3,LTR7chr19:39490389-39493428:+.alignment
chr19:39490389-39493428:+ENST00000595961.4ENSG00000105197.9TIMM50ncRNA_exonicAluJr,AluJb,AluJo,AluSx,MER102b,MIR,MIRb,AluSx1,AluSp,MER3,LTR7chr19:39490389-39493428:+.alignment
chr19:39490389-39493428:+ENST00000600878.1ENSG00000105197.9TIMM50ncRNA_exonicAluJr,AluJb,AluJo,AluSx,MER102b,MIR,MIRb,AluSx1,AluSp,MER3,LTR7chr19:39490389-39493428:+.alignment


Top

2. Tumor-specific enriched editing regions for TIMM50


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:39490389-39493428:+BRCAEER1.0111e-08image
ENSG00000105197.9,TIMM50BRCAEAG1.0323e-08image
chr19:39490389-39493428:+HNSCEER1.2194e-03image
ENSG00000105197.9,TIMM50HNSCEAG1.2056e-03image
chr19:39490389-39493428:+LIHCEER1.1086e-02image
ENSG00000105197.9,TIMM50LIHCEAG1.1086e-02image
chr19:39490389-39493428:+STADEER6.5045e-03image
ENSG00000105197.9,TIMM50STADEAG6.5939e-03image
chr19:39490389-39493428:+THCAEER8.2320e-06image
ENSG00000105197.9,TIMM50THCAEAG8.0235e-06image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:39490389-39493428:+THCAPathEER6.2289e-045.1000e-030.1247image
ENSG00000105197.9,TIMM50THCAPathEAG6.0284e-044.9948e-030.1250image
ENSG00000105197.9,TIMM50UCSCliEAG2.4097e-024.0265e-02-0.2750image
chr19:39490389-39493428:+UCSCliEER2.4672e-024.1152e-02-0.2738image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for TIMM50


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:39490389-39493428:+COADEERENSG00000220205,VAMP20.26081.7924e-031.4091e-170.4964imageNADAR;DGCR8;HNRNPC;IGF2BP2NADendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr19:39490389-39493428:+COADEERENSG00000263050,RP11-667K14.30.24214.1875e-031.5600e-210.5452imageNHNRNPCNANeutrophilsGSVA_HALLMARK_PEROXISOME
chr19:39490389-39493428:+KICHEERENSG00000156171,DRAM20.51393.8329e-029.4296e-040.4006imageNADAR;DGCR8;HNRNPC;IGF2BP2DRAM2MonocytesGSVA_HALLMARK_APOPTOSIS
chr19:39490389-39493428:+UCECEERENSG00000139192,TAPBPL0.34812.1920e-032.1259e-080.4100imageNDGCR8;HNRNPC;IGF2BP2TAPBPLT_cells_regulatory_(Tregs)GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr19:39490389-39493428:+UCECEERENSG00000204397,CARD160.24864.5758e-023.0704e-080.4057imageNADAR;DGCR8CARD16T_cells_CD8GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr19:39490389-39493428:+DLBCEERENSG00000133641,C12orf29-0.60731.5472e-026.5286e-06-0.6109imageNDGCR8;HNRNPC;IGF2BP2NANK_cells_restingGSVA_HALLMARK_G2M_CHECKPOINT
chr19:39490389-39493428:+DLBCEERENSG00000272010,CTD-3025N20.3-0.57872.0389e-026.0452e-04-0.4867imageNHNRNPC;IGF2BP2NAMast_cells_restingGSVA_HALLMARK_HYPOXIA
chr19:39490389-39493428:+DLBCEERENSG00000252361,RNU6-118P-0.56112.1704e-029.5144e-04-0.4711imageNNNAB_cells_naive
chr19:39490389-39493428:+DLBCEERENSG00000198464,ZNF480-0.56302.2730e-025.2191e-05-0.5599imageNADAR;DGCR8;HNRNPC;IGF2BP2NANK_cells_restingGSVA_HALLMARK_G2M_CHECKPOINT
chr19:39490389-39493428:+DLBCEERENSG00000257596,RP11-968A15.2-0.59312.3294e-025.5411e-05-0.5583imageNNNAMast_cells_activatedGSVA_HALLMARK_APICAL_SURFACE
chr19:39490389-39493428:+COADEERENSG00000220205,VAMP20.26081.7924e-031.4091e-170.4964imageNADAR;DGCR8;HNRNPC;IGF2BP2NADendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr19:39490389-39493428:+COADEERENSG00000263050,RP11-667K14.30.24214.1875e-031.5600e-210.5452imageNHNRNPCNANeutrophilsGSVA_HALLMARK_PEROXISOME
chr19:39490389-39493428:+KICHEERENSG00000156171,DRAM20.51393.8329e-029.4296e-040.4006imageNADAR;DGCR8;HNRNPC;IGF2BP2DRAM2MonocytesGSVA_HALLMARK_APOPTOSIS
chr19:39490389-39493428:+UCECEERENSG00000139192,TAPBPL0.34812.1920e-032.1259e-080.4100imageNDGCR8;HNRNPC;IGF2BP2TAPBPLT_cells_regulatory_(Tregs)GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr19:39490389-39493428:+UCECEERENSG00000204397,CARD160.24864.5758e-023.0704e-080.4057imageNADAR;DGCR8CARD16T_cells_CD8GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr19:39490389-39493428:+DLBCEERENSG00000133641,C12orf29-0.60731.5472e-026.5286e-06-0.6109imageNDGCR8;HNRNPC;IGF2BP2NANK_cells_restingGSVA_HALLMARK_G2M_CHECKPOINT
chr19:39490389-39493428:+DLBCEERENSG00000272010,CTD-3025N20.3-0.57872.0389e-026.0452e-04-0.4867imageNHNRNPC;IGF2BP2NAMast_cells_restingGSVA_HALLMARK_HYPOXIA
chr19:39490389-39493428:+DLBCEERENSG00000252361,RNU6-118P-0.56112.1704e-029.5144e-04-0.4711imageNNNAB_cells_naive
chr19:39490389-39493428:+DLBCEERENSG00000198464,ZNF480-0.56302.2730e-025.2191e-05-0.5599imageNADAR;DGCR8;HNRNPC;IGF2BP2NANK_cells_restingGSVA_HALLMARK_G2M_CHECKPOINT
chr19:39490389-39493428:+DLBCEERENSG00000257596,RP11-968A15.2-0.59312.3294e-025.5411e-05-0.5583imageNNNAMast_cells_activatedGSVA_HALLMARK_APICAL_SURFACE
chr19:39490389-39493428:+COADEERENSG00000220205,VAMP20.26081.7924e-031.4091e-170.4964imageNADAR;DGCR8;HNRNPC;IGF2BP2NADendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr19:39490389-39493428:+COADEERENSG00000263050,RP11-667K14.30.24214.1875e-031.5600e-210.5452imageNHNRNPCNANeutrophilsGSVA_HALLMARK_PEROXISOME
chr19:39490389-39493428:+KICHEERENSG00000156171,DRAM20.51393.8329e-029.4296e-040.4006imageNADAR;DGCR8;HNRNPC;IGF2BP2DRAM2MonocytesGSVA_HALLMARK_APOPTOSIS
chr19:39490389-39493428:+UCECEERENSG00000139192,TAPBPL0.34812.1920e-032.1259e-080.4100imageNDGCR8;HNRNPC;IGF2BP2TAPBPLT_cells_regulatory_(Tregs)GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr19:39490389-39493428:+UCECEERENSG00000204397,CARD160.24864.5758e-023.0704e-080.4057imageNADAR;DGCR8CARD16T_cells_CD8GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr19:39490389-39493428:+DLBCEERENSG00000133641,C12orf29-0.60731.5472e-026.5286e-06-0.6109imageNDGCR8;HNRNPC;IGF2BP2NANK_cells_restingGSVA_HALLMARK_G2M_CHECKPOINT
chr19:39490389-39493428:+DLBCEERENSG00000272010,CTD-3025N20.3-0.57872.0389e-026.0452e-04-0.4867imageNHNRNPC;IGF2BP2NAMast_cells_restingGSVA_HALLMARK_HYPOXIA
chr19:39490389-39493428:+DLBCEERENSG00000252361,RNU6-118P-0.56112.1704e-029.5144e-04-0.4711imageNNNAB_cells_naive
chr19:39490389-39493428:+DLBCEERENSG00000198464,ZNF480-0.56302.2730e-025.2191e-05-0.5599imageNADAR;DGCR8;HNRNPC;IGF2BP2NANK_cells_restingGSVA_HALLMARK_G2M_CHECKPOINT
chr19:39490389-39493428:+DLBCEERENSG00000257596,RP11-968A15.2-0.59312.3294e-025.5411e-05-0.5583imageNNNAMast_cells_activatedGSVA_HALLMARK_APICAL_SURFACE

More results



Top

4. Enriched editing regions and immune related splicing for TIMM50


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000105197.9,TIMM50
COADEAGIRENSG00000168488.14chr1628835932:28836122:28836448:28836485-0.21974.8833e-026.1797e-15-0.4595imageNACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL14;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RC3H1;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000105197.9,TIMM50
COADEAGIRENSG00000170037.9chr177948486:7949157:7949384:7949425-0.21824.9366e-021.6647e-110.4054imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184CNTROBEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:39490389-39493428:+
COADEERIRENSG00000167925.11chr1742192905:42193027:42193316:42193594-0.23182.6453e-023.4637e-210.5439imageNADAR;DGCR8;HNRNPC;IGF2BP2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:39490389-39493428:+
COADEERIRENSG00000167721.6chr172322502:2324374:2324503:23245540.23572.7162e-023.7435e-260.5937imageNADAR;DGCR8;HNRNPC;IGF2BP2NANeutrophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr19:39490389-39493428:+
COADEERIRENSG00000168488.14chr1628835932:28836122:28836448:28836485-0.21964.3856e-026.1879e-15-0.4595imageNADAR;DGCR8;HNRNPC;IGF2BP2NADendritic_cells_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr19:39490389-39493428:+
COADEERIRENSG00000170037.9chr177948486:7949157:7949384:7949425-0.21814.4377e-021.6640e-110.4054imageNADAR;DGCR8;HNRNPC;IGF2BP2CNTROBEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000105197.9,TIMM50
COADEAGIRENSG00000167925.11chr1742192905:42193027:42193316:42193594-0.23192.9912e-023.4698e-210.5439imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;TNRC6A;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:39490389-39493428:+
COADEERIRENSG00000136930.8chr9124353465:124353709:124356763:1243569150.22204.6293e-026.4673e-230.5606imageNADAR;DGCR8;HNRNPC;IGF2BP2PSMB7EosinophilsGSVA_HALLMARK_DNA_REPAIR
ENSG00000105197.9,TIMM50
COADEAGIRENSG00000167721.6chr172322502:2324374:2324503:23245540.23573.0892e-023.7428e-260.5937imageNACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;WTAP;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NANeutrophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr19:39490389-39493428:+
COADEERIRENSG00000205220.7chr1667934796:67934948:67935419:67935478-0.22682.9968e-024.0975e-200.5312imageNIGF2BP2PSMB10EosinophilsGSVA_HALLMARK_UV_RESPONSE_UP

More results



Top

5. Enriched editing regions and immune infiltration for TIMM50


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:39490389-39493428:+ACCEERMast_cells_resting1.5311e-020.2848image
ENSG00000105197.9,TIMM50ACCEAGMast_cells_resting1.5311e-020.2848image
chr19:39490389-39493428:+BLCAEERMacrophages_M11.0282e-030.1689image
ENSG00000105197.9,TIMM50BLCAEAGMacrophages_M19.8939e-040.1694image
chr19:39490389-39493428:+BRCAEERMast_cells_activated2.2590e-02-0.0699image
ENSG00000105197.9,TIMM50BRCAEAGT_cells_gamma_delta2.2555e-020.0699image
chr19:39490389-39493428:+CESCEERNeutrophils3.3060e-030.1705image
ENSG00000105197.9,TIMM50CESCEAGNeutrophils3.3054e-030.1705image
chr19:39490389-39493428:+CHOLEERMonocytes2.0816e-02-0.3949image
ENSG00000105197.9,TIMM50CHOLEAGMonocytes2.0816e-02-0.3949image
chr19:39490389-39493428:+COADEEREosinophils3.2678e-040.2211image
ENSG00000105197.9,TIMM50COADEAGEosinophils3.2671e-040.2211image
chr19:39490389-39493428:+DLBCEERT_cells_gamma_delta7.4101e-040.4798image
ENSG00000105197.9,TIMM50DLBCEAGT_cells_gamma_delta7.4101e-040.4798image
chr19:39490389-39493428:+ESCAEERMonocytes6.7525e-03-0.2134image
ENSG00000105197.9,TIMM50ESCAEAGMonocytes6.3413e-03-0.2149image
chr19:39490389-39493428:+GBMEERMonocytes1.4815e-060.3635image
ENSG00000105197.9,TIMM50GBMEAGMonocytes1.4336e-060.3640image
chr19:39490389-39493428:+HNSCEERT_cells_regulatory_(Tregs)1.3174e-02-0.1144image
ENSG00000105197.9,TIMM50HNSCEAGT_cells_regulatory_(Tregs)1.3090e-02-0.1145image
chr19:39490389-39493428:+KICHEERNeutrophils2.5605e-030.3680image
ENSG00000105197.9,TIMM50KICHEAGNeutrophils2.5605e-030.3680image
chr19:39490389-39493428:+KIRCEERT_cells_gamma_delta3.8929e-030.1480image
ENSG00000105197.9,TIMM50KIRCEAGT_cells_gamma_delta4.1410e-030.1470image
chr19:39490389-39493428:+KIRPEERT_cells_CD4_naive5.9078e-040.2026image
ENSG00000105197.9,TIMM50KIRPEAGT_cells_CD4_naive7.1062e-040.1997image
chr19:39490389-39493428:+LGGEERT_cells_regulatory_(Tregs)1.3570e-020.1073image
ENSG00000105197.9,TIMM50LGGEAGT_cells_regulatory_(Tregs)1.3071e-020.1078image
chr19:39490389-39493428:+LUADEERDendritic_cells_activated3.9046e-020.0952image
ENSG00000105197.9,TIMM50LUADEAGDendritic_cells_activated3.9036e-020.0952image
chr19:39490389-39493428:+LUSCEERNK_cells_resting5.5731e-030.1273image
ENSG00000105197.9,TIMM50LUSCEAGNK_cells_resting5.6553e-030.1270image
chr19:39490389-39493428:+MESOEERT_cells_CD83.2606e-020.2392image
ENSG00000105197.9,TIMM50MESOEAGT_cells_CD83.2606e-020.2392image
chr19:39483922-39485272:+OVEERNK_cells_resting8.2330e-050.5015image
chr19:39490389-39493428:+OVEERMacrophages_M04.4494e-04-0.2042image
ENSG00000105197.9,TIMM50OVEAGMacrophages_M03.9392e-04-0.2061image
chr19:39490389-39493428:+PAADEERT_cells_CD4_memory_activated5.0306e-03-0.2221image
ENSG00000105197.9,TIMM50PAADEAGT_cells_CD4_memory_activated4.9675e-03-0.2224image
chr19:39490389-39493428:+PCPGEERT_cells_CD4_memory_resting7.2382e-03-0.2007image
ENSG00000105197.9,TIMM50PCPGEAGT_cells_CD4_memory_resting7.5733e-03-0.1996image
chr19:39490389-39493428:+PRADEERB_cells_naive8.9188e-030.1174image
ENSG00000105197.9,TIMM50PRADEAGB_cells_naive9.7801e-030.1160image
chr19:39490389-39493428:+READEERDendritic_cells_activated3.7364e-02-0.2139image
ENSG00000105197.9,TIMM50READEAGDendritic_cells_activated3.7527e-02-0.2138image
chr19:39490389-39493428:+SARCEERMonocytes1.5665e-02-0.1543image
ENSG00000105197.9,TIMM50SARCEAGMonocytes1.5654e-02-0.1543image
chr19:39490389-39493428:+SKCMEERT_cells_CD81.4353e-100.2899image
ENSG00000105197.9,TIMM50SKCMEAGT_cells_CD81.3588e-100.2902image
chr19:39490389-39493428:+STADEERMonocytes1.0352e-030.1734image
ENSG00000105197.9,TIMM50STADEAGMonocytes1.0989e-030.1725image
chr19:39490389-39493428:+TGCTEERT_cells_regulatory_(Tregs)1.2766e-020.2016image
ENSG00000105197.9,TIMM50TGCTEAGT_cells_regulatory_(Tregs)1.2787e-020.2015image
chr19:39490389-39493428:+THCAEERT_cells_CD4_memory_activated7.7251e-070.2180image
ENSG00000105197.9,TIMM50THCAEAGT_cells_CD4_memory_activated7.2823e-070.2185image
chr19:39490389-39493428:+THYMEERT_cells_CD4_naive2.7671e-06-0.4178image
ENSG00000105197.9,TIMM50THYMEAGT_cells_CD4_naive2.8709e-06-0.4172image
chr19:39490389-39493428:+UCECEERT_cells_regulatory_(Tregs)4.3411e-030.2159image
ENSG00000105197.9,TIMM50UCECEAGT_cells_regulatory_(Tregs)4.3913e-030.2156image
chr19:39490389-39493428:+UCSEEREosinophils1.2285e-02-0.3325image
ENSG00000105197.9,TIMM50UCSEAGEosinophils1.1992e-02-0.3336image
chr19:39490389-39493428:+UVMEERT_cells_CD82.0105e-020.2595image
ENSG00000105197.9,TIMM50UVMEAGT_cells_CD82.0203e-020.2593image


Top

6. Enriched editing regions and immune gene sets for TIMM50


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr19:39490389-39493428:+STADEER2.6485e-02image7.4220e-050.2087image
ENSG00000105197.9,TIMM50STADEAG2.6978e-02image8.2504e-050.2074image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000105197.9,TIMM50ACCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6344e-030.3493image
chr19:39490389-39493428:+ACCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6344e-030.3493image
ENSG00000105197.9,TIMM50BLCAGSVA_HALLMARK_COMPLEMENTEAG1.6508e-110.3386image
chr19:39490389-39493428:+BLCAGSVA_HALLMARK_COMPLEMENTEER1.9515e-110.3374image
ENSG00000105197.9,TIMM50BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.1125e-150.2399image
chr19:39490389-39493428:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2661e-150.2396image
chr19:39490389-39493428:+CESCGSVA_HALLMARK_COMPLEMENTEER9.6560e-080.3044image
ENSG00000105197.9,TIMM50CESCGSVA_HALLMARK_COMPLEMENTEAG9.7046e-080.3044image
ENSG00000105197.9,TIMM50CHOLGSVA_HALLMARK_DNA_REPAIREAG3.7852e-02-0.3576image
chr19:39490389-39493428:+CHOLGSVA_HALLMARK_DNA_REPAIREER3.7852e-02-0.3576image
chr19:39490389-39493428:+COADGSVA_HALLMARK_MYC_TARGETS_V2EER1.8841e-05-0.2619image
ENSG00000105197.9,TIMM50COADGSVA_HALLMARK_MYC_TARGETS_V2EAG1.8827e-05-0.2620image
ENSG00000105197.9,TIMM50DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.1207e-030.4653image
chr19:39490389-39493428:+DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.1207e-030.4653image
chr19:39490389-39493428:+ESCAGSVA_HALLMARK_PROTEIN_SECRETIONEER6.1860e-050.3112image
ENSG00000105197.9,TIMM50ESCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.7451e-050.3097image
ENSG00000105197.9,TIMM50GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.4336e-100.4663image
chr19:39490389-39493428:+GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.1775e-100.4674image
ENSG00000105197.9,TIMM50HNSCGSVA_HALLMARK_P53_PATHWAYEAG1.1266e-070.2420image
chr19:39490389-39493428:+HNSCGSVA_HALLMARK_P53_PATHWAYEER1.0689e-070.2424image
chr19:39490389-39493428:+KICHGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER6.1291e-030.3365image
ENSG00000105197.9,TIMM50KICHGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG6.1291e-030.3365image
ENSG00000105197.9,TIMM50KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4965e-040.1936image
chr19:39490389-39493428:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4390e-040.1940image
chr19:39490389-39493428:+KIRPGSVA_HALLMARK_GLYCOLYSISEER2.2128e-050.2489image
ENSG00000105197.9,TIMM50KIRPGSVA_HALLMARK_GLYCOLYSISEAG2.5880e-050.2468image
ENSG00000105197.9,TIMM50LAMLGSVA_HALLMARK_APICAL_JUNCTIONEAG7.3879e-030.2718image
chr19:39490389-39493428:+LAMLGSVA_HALLMARK_APICAL_JUNCTIONEER7.4402e-030.2716image
ENSG00000105197.9,TIMM50LGGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.1686e-13-0.3082image
chr19:39490389-39493428:+LGGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.2685e-13-0.3081image
chr19:39490389-39493428:+LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.4694e-040.2097image
ENSG00000105197.9,TIMM50LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.4694e-040.2097image
ENSG00000105197.9,TIMM50LUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG9.1476e-070.2242image
chr19:39490389-39493428:+LUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER8.8405e-070.2244image
chr19:39490389-39493428:+LUSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER8.4832e-070.2241image
ENSG00000105197.9,TIMM50LUSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG9.2646e-070.2233image
ENSG00000105197.9,TIMM50OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG5.7904e-140.4209image
chr19:39483922-39485272:+OVGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.6852e-02-0.3182image
chr19:39490389-39493428:+OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER5.7323e-140.4209image
chr19:39490389-39493428:+PAADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER3.8435e-02-0.1649image
ENSG00000105197.9,TIMM50PAADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG3.7994e-02-0.1652image
ENSG00000105197.9,TIMM50PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.9067e-020.1477image
chr19:39490389-39493428:+PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.5941e-020.1498image
chr19:39490389-39493428:+PRADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.4668e-100.2829image
ENSG00000105197.9,TIMM50PRADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.7245e-100.2818image
ENSG00000105197.9,TIMM50READGSVA_HALLMARK_KRAS_SIGNALING_UPEAG2.6391e-030.3051image
chr19:39490389-39493428:+READGSVA_HALLMARK_KRAS_SIGNALING_UPEER2.6688e-030.3048image
ENSG00000105197.9,TIMM50SARCGSVA_HALLMARK_COAGULATIONEAG1.6993e-040.2380image
chr19:39490389-39493428:+SARCGSVA_HALLMARK_COAGULATIONEER1.7049e-040.2379image
ENSG00000105197.9,TIMM50SKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.1556e-180.3852image
chr19:39483922-39485272:+SKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.3708e-020.2560image
chr19:39490389-39493428:+SKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.9801e-180.3828image
chr19:39490389-39493428:+STADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER7.4220e-050.2087image
ENSG00000105197.9,TIMM50STADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG8.2504e-050.2074image
chr19:39490389-39493428:+TGCTGSVA_HALLMARK_KRAS_SIGNALING_UPEER5.0553e-060.3605image
ENSG00000105197.9,TIMM50TGCTGSVA_HALLMARK_KRAS_SIGNALING_UPEAG5.0713e-060.3605image
ENSG00000105197.9,TIMM50THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG7.2447e-210.4008image
chr19:39490389-39493428:+THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER6.8887e-210.4010image
chr19:39490389-39493428:+THYMGSVA_HALLMARK_G2M_CHECKPOINTEER1.5621e-05-0.3878image
ENSG00000105197.9,TIMM50THYMGSVA_HALLMARK_G2M_CHECKPOINTEAG1.5917e-05-0.3874image
chr19:39490389-39493428:+UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.3591e-040.2695image
ENSG00000105197.9,TIMM50UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.2923e-040.2699image
chr19:39490389-39493428:+UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.0354e-040.4652image
ENSG00000105197.9,TIMM50UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.8662e-040.4669image
ENSG00000105197.9,TIMM50UVMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.5385e-050.4629image
chr19:39490389-39493428:+UVMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.4956e-050.4635image


Top

7. Enriched editing regions and drugs for TIMM50


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:39490389-39493428:+ACCBleomycinEER4.8932e-040.4006image
ENSG00000105197.9,TIMM50ACCBleomycinEAG4.8932e-040.4006image
ENSG00000105197.9,TIMM50BLCACGP.60474EAG1.1094e-09-0.3080image
chr19:39490389-39493428:+BLCACGP.60474EER1.2850e-09-0.3068image
ENSG00000105197.9,TIMM50BRCALapatinibEAG6.7733e-07-0.1521image
chr19:39490389-39493428:+BRCALapatinibEER6.8965e-07-0.1520image
ENSG00000105197.9,TIMM50CESCCGP.60474EAG1.0688e-05-0.2532image
chr19:39490389-39493428:+CESCCGP.60474EER1.0702e-05-0.2532image
ENSG00000105197.9,TIMM50CHOLAZD6482EAG1.2558e-02-0.4236image
chr19:39490389-39493428:+CHOLAZD6482EER1.2558e-02-0.4236image
ENSG00000105197.9,TIMM50COADLFM.A13EAG4.4799e-06-0.2802image
chr19:39490389-39493428:+COADLFM.A13EER4.4820e-06-0.2802image
ENSG00000105197.9,TIMM50DLBCGNF.2EAG3.8627e-04-0.5014image
chr19:39490389-39493428:+DLBCGNF.2EER3.8627e-04-0.5014image
chr19:39490389-39493428:+ESCABexaroteneEER2.9911e-04-0.2822image
ENSG00000105197.9,TIMM50ESCABexaroteneEAG2.9326e-04-0.2826image
ENSG00000105197.9,TIMM50GBMBIBW2992EAG9.8064e-11-0.4752image
chr19:39490389-39493428:+GBMBIBW2992EER9.5944e-11-0.4755image
ENSG00000105197.9,TIMM50HNSCCI.1040EAG3.0287e-10-0.2855image
chr19:39490389-39493428:+HNSCCI.1040EER3.0533e-10-0.2854image
ENSG00000105197.9,TIMM50KICHFTI.277EAG3.3105e-07-0.5838image
chr19:39490389-39493428:+KICHFTI.277EER3.3105e-07-0.5838image
ENSG00000105197.9,TIMM50KIRCCI.1040EAG4.3570e-08-0.2767image
chr19:39490389-39493428:+KIRCCI.1040EER4.0455e-08-0.2773image
chr19:39490389-39493428:+KIRPDMOGEER4.1617e-06-0.2693image
ENSG00000105197.9,TIMM50KIRPDMOGEAG4.4081e-06-0.2686image
chr19:39490389-39493428:+LAMLBicalutamideEER4.1541e-02-0.2085image
ENSG00000105197.9,TIMM50LAMLBicalutamideEAG4.2468e-02-0.2075image
ENSG00000105197.9,TIMM50LGGEpothilone.BEAG4.4735e-490.5810image
chr19:39490389-39493428:+LGGEpothilone.BEER3.6468e-490.5814image
chr19:39490389-39493428:+LIHCGSK.650394EER8.9848e-050.2162image
ENSG00000105197.9,TIMM50LIHCGSK.650394EAG8.9848e-050.2162image
ENSG00000105197.9,TIMM50LUADCI.1040EAG3.7108e-05-0.1891image
chr19:39490389-39493428:+LUADCI.1040EER3.9279e-05-0.1885image
chr19:39483922-39485272:+LUSCAKT.inhibitor.VIIIEER4.4747e-020.3630image
chr19:39490389-39493428:+LUSCAICAREER4.4175e-05-0.1866image
ENSG00000105197.9,TIMM50LUSCAICAREAG4.4363e-05-0.1866image
chr19:39490389-39493428:+MESOBMS.708163EER1.5572e-03-0.3481image
ENSG00000105197.9,TIMM50MESOBMS.708163EAG1.5572e-03-0.3481image
ENSG00000105197.9,TIMM50OVABT.263EAG3.4077e-060.2680image
chr19:39483922-39485272:+OVDoxorubicinEER5.2019e-04-0.4489image
chr19:39490389-39493428:+OVABT.263EER3.5280e-060.2676image
chr19:39490389-39493428:+PAADABT.263EER4.3328e-030.2294image
ENSG00000105197.9,TIMM50PAADABT.263EAG4.2957e-030.2296image
ENSG00000105197.9,TIMM50PCPGBI.2536EAG5.9881e-030.2052image
chr19:39490389-39493428:+PCPGBI.2536EER6.2088e-030.2044image
chr19:39490389-39493428:+PRADGNF.2EER1.3629e-05-0.1945image
ENSG00000105197.9,TIMM50PRADBortezomibEAG1.3604e-05-0.1942image
ENSG00000105197.9,TIMM50READBIRB.0796EAG2.0149e-040.3725image
chr19:39490389-39493428:+READBIRB.0796EER1.9912e-040.3728image
ENSG00000105197.9,TIMM50SARCA.770041EAG3.7340e-05-0.2607image
chr19:39490389-39493428:+SARCA.770041EER3.7291e-05-0.2608image
chr19:39483922-39485272:+SKCMJNK.9LEER5.1440e-040.4073image
ENSG00000105197.9,TIMM50SKCMDMOGEAG2.4321e-11-0.3013image
chr19:39490389-39493428:+SKCMDMOGEER3.1879e-11-0.2996image
ENSG00000105197.9,TIMM50STADAZ628EAG2.9857e-05-0.2196image
chr19:39490389-39493428:+STADAZ628EER2.7347e-05-0.2206image
chr19:39490389-39493428:+TGCTBMS.536924EER2.9710e-06-0.3686image
ENSG00000105197.9,TIMM50TGCTBMS.536924EAG2.9968e-06-0.3685image
ENSG00000105197.9,TIMM50THCACI.1040EAG1.1312e-22-0.4174image
chr19:39490389-39493428:+THCACI.1040EER1.0820e-22-0.4176image
chr19:39490389-39493428:+THYMDoxorubicinEER6.5722e-080.4743image
ENSG00000105197.9,TIMM50THYMDoxorubicinEAG6.2842e-080.4750image
chr19:39490389-39493428:+UCECAZD6244EER9.1558e-06-0.3311image
ENSG00000105197.9,TIMM50UCECAZD6244EAG9.1004e-06-0.3312image
chr19:39490389-39493428:+UCSCMKEER3.4753e-050.5235image
ENSG00000105197.9,TIMM50UCSCMKEAG3.4384e-050.5237image
ENSG00000105197.9,TIMM50UVMEpothilone.BEAG3.3663e-050.4461image
chr19:39490389-39493428:+UVMEpothilone.BEER3.5477e-050.4449image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType